doi:10.3969/j.issn.1004-583X.2021.05.017

Abstract

CLC Number:

R587.1

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.05.017

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I5/471

References 36

[1]	Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus[J]. N Engl J Med, 1993, 329(14):977-986. doi: 10.1056/NEJM199309303291401 URL
[2]	中华医学会糖尿病学分会. 中国血糖监测临床应用指南(2015年版)[J]. 中华糖尿病杂志, 2015, 7(10):603-613.
[3]	Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring[J]. Diabetes Care, 2017, 40(12):1631-1640. doi: 10.2337/dc17-1600 URL
[4]	Runge AS, Kennedy L, Brown AS, et al. Does time-in-range matter perspectives from people with diabetes on the success of current therapies and the drivers of improved outcomes[J]. Clinical Diabetes, 2018, 36(2):112-119. doi: 10.2337/cd17-0094 pmid: 29686449
[5]	陈莉明. 技术引领科研,循证助力指南:血糖监测研究新进展[J]. 中华糖尿病杂志, 2020, 12(1):21-24.
[6]	Beck RW, Connor CG, Mullen DM, et al. The fallacy of average: How using HbA₁c alone to assess glycemic control can be misleading[J]. Diabetes Care, 2017, 40(8):994-999. doi: 10.2337/dc17-0636 pmid: 28733374
[7]	Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range[J]. Diabetes Care, 2019, 42(8):1593-1603. doi: 10.2337/dci19-0028 pmid: 31177185
[8]	Beyond A1C Writing Group. Need for regulatory change to incorporate beyond A1C glycemic metrics[J]. Diabetes Care, 2018, 41(6):e92-e94. doi: 10.2337/dci18-0010 URL
[9]	Agiostratidou G, Anhalt H, Ball D, et al. Standardizing clinically meaningful outcome measures beyond HbA₁c for type 1 diabetes: A consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange[J]. Diabetes Care, 2017, 40(12):1622-1630. doi: 10.2337/dc17-1624 pmid: 29162582
[10]	Rhee MK, Ho YL, Raghavan S, et al. Random plasma glucose predicts the diagnosis of diabetes[J]. PLoS One, 2019, 14(7):e0219964. doi: 10.1371/journal.pone.0219964 URL
[11]	International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: A joint position statement of the American diabetes association and the european association for the study of diabetes[J]. Diabetologia, 2017, 60(1):3-6. doi: 10.1007/s00125-016-4146-6 URL
[12]	American Diabetes Association.14. Management of diabetes in pregnancy: Standards of medical care in diabetes-2019[J]. Diabetes Care, 2019, 42(Suppl 1):S165-S172. doi: 10.2337/dc19-S014 URL
[13]	Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): A multicentre international randomised controlled trial[J]. Lancet, 2017, 390(10110):2347-2359. doi: 10.1016/S0140-6736(17)32400-5 URL
[14]	Kristensen K, Ogge LE, Sengpiel V, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes: An observational cohort study of 186 pregnancies[J]. Diabetologia, 2019, 62(7):1143-1153. doi: 10.1007/s00125-019-4850-0 pmid: 30904938
[15]	Kovatchev BP. Metrics for glycaemic control - from HbA₁c to continuous glucose monitoring[J]. Nat Rev Endocrinol, 2017, 13(7):425-436. doi: 10.1038/nrendo.2017.3 pmid: 28304392
[16]	Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes[J]. Diabetes Technol Ther, 2019, 21(2):81-85. doi: 10.1089/dia.2018.0310 URL
[17]	Hirsch IB, Welsh JB, Calhoun P, et al. Associations between HbA₁c and continuous glucose monitoring-derived glycaemic variables[J]. Diabet Med, 2019, 36(12):1637-1642. doi: 10.1111/dme.v36.12 URL
[18]	Cryer PE. Glycemic goals in diabetes: Trade-off between glycemic control and iatrogenic hypoglycemia[J]. Diabetes, 2014, 63(7):2188-2195. doi: 10.2337/db14-0059 URL
[19]	Bergenstal RM. Glycemic variability and diabetes complications: Does it matter Simply put, there are better glycemic markers![J] Diabetes Care, 2015, 38(8):1615-1621. doi: 10.2337/dc15-0099 pmid: 26207055
[20]	Rodbard D. Display of glucose distributions by date, time of day, and day of week: New and improved methods[J]. J Diabetes Sci Technol, 2009, 3(6):1388-1394. pmid: 20144393
[21]	Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes[J]. Diabetes Care, 2018, 41(11) :2370-2376. doi: 10.2337/dc18-1131 URL
[22]	Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials[J]. Diabetes Care, 2019, 42(3):400-405. doi: 10.2337/dc18-1444 pmid: 30352896
[23]	Mayeda L, Katz R, Ahmad I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease[J]. BMJ Open Diabetes Res Care, 2020, 8(1):e000991. doi: 10.1136/bmjdrc-2019-000991 URL
[24]	Beck RW, Bergenstal RM, Cheng P, et al. The relationships between time in range, hyperglycemia metrics, and HbA₁c[J]. J Diabetes Sci Technol, 2019, 13(4):614-626. doi: 10.1177/1932296818822496 pmid: 30636519
[25]	Murphy HR. Continuous glucose monitoring targets in type 1 diabetes pregnancy: Every 5% time in range matters[J]. Diabetologia, 2019, 62(7):1123-1128. doi: 10.1007/s00125-019-4904-3 pmid: 31161344
[26]	Vos FE, Schollum JB, Coulter CV, et al. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring[J]. Nephrology (Carlton), 2012, 17(2):182-188. doi: 10.1111/nep.2012.17.issue-2 URL
[27]	Bergenstal RM, Gal RL, Connor CG, et al. Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels[J]. Ann Intern Med, 2017, 167(2):95-102. doi: 10.7326/M16-2596 pmid: 28605777
[28]	Cohen RM, Franco RS, Smith EP, et al. When HbA₁c and blood glucose do not match: How much is determined by race, by genetics, by differences in mean red blood cell age?[J]. J Clin Endocrinol Metab, 2019, 104(3):707-710. doi: 10.1210/jc.2018-02409 URL
[29]	Brahimi N, Potier L, Mohammedi K. Cutaneous adverse events related to FreeStyle Libre device[J]. Lancet, 2017, 389(10077):1396. doi: 10.1016/S0140-6736(17)30896-6
[30]	Herman A, Aerts O, Baeck M, et al. Allergic contact dermatitis caused by isobornyl acrylate in Freestyle(R) Libre, a newly introduced glucose sensor[J]. Contact Dermatitis, 2017, 77(6):367-373. doi: 10.1111/cod.12866 pmid: 28804907
[31]	Tanenbaum ML, Hanes SJ, Miller KM, et al. Diabetes device use in adults with type 1 diabetes: Barriers to uptake and potential intervention targets[J]. Diabetes Care, 2017, 40(2):181-187. doi: 10.2337/dc16-1536 pmid: 27899489
[32]	Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: Meta-analysis of randomised controlled trials using individual patient data[J]. BMJ, 2011, 343:d3805. doi: 10.1136/bmj.d3805 URL
[33]	Vigersky RA, Shin J, Jiang B, et al. The comprehensive glucose pentagon: A glucose-centric composite metric for assessing glycemic control in persons with diabetes[J]. J Diabetes Sci Technol, 2018, 12(1):114-123. doi: 10.1177/1932296817718561 pmid: 28748705
[34]	Hempe JM, Liu S, Myers L, et al. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial[J]. Diabetes Care, 2015, 38(6):1067-1074. doi: 10.2337/dc14-1844 URL
[35]	Peyser TA, Balo AK, Buckingham BA, et al. Glycemic variability percentage: A novel method for assessing glycemic variability from continuous glucose monitor data[J]. Diabetes Technol Ther, 2018, 20(1):6-16. doi: 10.1089/dia.2017.0187 URL
[36]	Rodbard D. Metrics to evaluate quality of glycemic control: Comparison of time in target, hypoglycemic, and hyperglycemic ranges with “risk indices”[J]. Diabetes Technol Ther, 2018, 20(5):325-334. doi: 10.1089/dia.2017.0416 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 36

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Lv Shasha, Song Jinlan, Shi Jian. Mitochondrial mutation m.3243A> G associated with diabetes mellitus: One case report and literature review [J]. Clinical Focus, 2024, 39(2): 160-163.
[2]	Zhang Jianan, Sun Linlin, Zhan Xiaoyan, Li Bing. Correlation between serum Vitamin B₁₂ and mild cognitive impairment in elderly patients with type 2 diabetes mellitus [J]. Clinical Focus, 2024, 39(1): 34-37.
[3]	Liao Kunfeng, Yao Yisong, Yang Jinpan, Yang Xining, Li Yaru, Zhou Hongyan, Liang Piao. Status and influencing factors of fear of progression in patients with type 2 diabetes mellitus [J]. Clinical Focus, 2023, 38(12): 1095-1100.
[4]	Shi Peihua, Lin Yanlin, Bi Lifang. Study on the correlation of NLR, PLR and MLR with type 2 diabetes mellitus complicated with coronary heart disease [J]. Clinical Focus, 2023, 38(11): 996-1001.
[5]	Yang Xin, Xu Huajiao. Bibliometric analysis of literatures reporting psychological intervention of patients with diabetes mellitus: Based on Web of Science [J]. Clinical Focus, 2023, 38(8): 731-736.
[6]	Jin Jiahui, Yang Yang, Qin Tong, He Yuxin, Su Meihua. Probiotic supplementation on improving glucose metabolism in patients with type 2 diabetes mellitus: A meta-analysis [J]. Clinical Focus, 2023, 38(7): 581-587.
[7]	Wu Yanan, Yan Tianmei, Liang Peng, Wei Limin. High-risk identification of depressive symptoms in middle-elderly patients with diabetes [J]. Clinical Focus, 2023, 38(6): 516-520.
[8]	Yang Minxing, Sun Lu, Ye Yun, Xu Wendong, Huang Xiaolin, Zhang Haiyun, Xu Yinglei. Characteristics of cognitive function and corresponding factors in young and middle-aged patients with type 2 diabetes with obstructive sleep apnea hypopnea syndrome [J]. Clinical Focus, 2023, 38(3): 216-220.
[9]	Rao Xiaojuan, Shi Shuangwei, Sang Yanhong. Comparison of short-term efficacy of insulin degludec/insulin versus continuous subcutaneous infusion of insulin asparton diabetic patients admitted in non-endocrinology departments [J]. Clinical Focus, 2023, 38(2): 132-136.
[10]	Xie Feifei, Zhang Weijian. Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A meta-analysis [J]. Clinical Focus, 2023, 38(1): 20-36.
[11]	Wang Cui, Lin Hao, Wu Pingping, Zhang Yali, Ren Jian, Xu Ting, Dong Guoyu, Zai Guotian. Correlation between hyperhomocysteinemia and early renal disease in patients with type 2 diabetes mellitus [J]. Clinical Focus, 2023, 38(1): 42-45.
[12]	. [J]. Clinical Focus, 2023, 38(1): 79-83.
[13]	Wang Runqing, Wang Qian, Liao Jianxiong. A network meta-analysis of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes [J]. Clinical Focus, 2022, 37(12): 1061-1073.
[14]	Wang Wenqi, Zhang Tao. Effect of semaglutide on total myocardial ischemic burden and serum inflammatory factors in patients with type 2 diabetes mellitus complicated with coronary heart disease [J]. Clinical Focus, 2022, 37(11): 996-1000.
[15]	. [J]. Clinical Focus, 2022, 37(10): 953-956.